A murine monoclonal antibody (15H6) against the trichothecene mycotoxin T-2 was capable of neutralizing the in vitro protein synthesis inhibitory effect of T-2 toxin in human B lymphoblastoid cultures. It was further shown that 15H6 given to rats (250 mg/kg) 30 min before or 15 min after a lethal dose (1 mg/kg) of T-2 toxin conferred 100% survival. A lower dose of 15H6 (125 mg/kg), given 15 min after the lethal dose of T-2 toxin, protected 25% of the rats. An increased time to death and 45% survival was seen in rats given the full dose of 15H6 antibody 60 min after lethal toxin. These data are the first demonstration of effective prophylaxis and therapy for T-2 toxemia.
specificity for both T-2 toxin and its major metabolite, HT-2 toxin, but does not bind to other closely related trichothecenes (14) . Previous studies have indicated that antibodies can neutralize in vitro toxic effects and provide in vivo protection against drugs (15) (16) (17) (18) and certain low molecular weight toxins (19) (20) (21) (22) (23) . We now report that monoclonal anti-T-2 antibody can neutralize the in vitro protein synthesis inhibition of T-2 toxin and protect rats against lethal T-2 toxemia.
Methods
In vitro studies. Protein synthesis inhibition was studied essentially as described earlier (14) . USU-9-l 1 3-IIA7, a human B lymphoblastoid cell line isolated in our laboratory from a human spleen, was maintained in vitro in RPMI 1640 medium supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 1% nonessential amino acids, 50 ;g/ml gentamicin, and 10% fetal bovine serum (HyClone Laboratories, Sterile Systems, Inc., Logan, UT). The affinity-purified mouse monoclonal anti-T-2 antibody (15H6)' used in this study was described earlier (14) . The neutralizing effect of anti-T-2 was measured by preincubation of various concentrations of T-2 toxin with various concentrations of anti-T-2 antibody for 30 min at room temperature. This was followed by the addition of aliquots of the antibody-toxin mixtures to flat-bottomed microtiter plates containing 1.0 X 10' cells in 100 ,d of leucine-free RPMI 1640 medium plus supplements. The cells were then pulsed with 0.5 M4Ci
[3H]leucine (40-60 Ci/mmol, Amersham Corp., Arlington Heights, IL). After 16-18-h incubation in a humidified 6% C02-94% air atmosphere at 37°C the cells were extracted with 5% trichloroacetic acid, harvested on glass fibers, and counted in aqueous scintillation cocktail (Beckman Instruments, Inc., Fullerton, CA).
In vivo studies. Male Sprague-Dawley rats (270-300 g) were anesthetized with halothane (2% in oxygen) and both femoral arteries cannulated with PE-50 tubing filled with heparinized 0.9% NaCI (sterile, pyrogen free, 100 U/ml). The tubing was then tunneled under the skin of the back to emerge at the back of the neck where both lines were secured by a spring wire (24) . The rats were then allowed to recover from surgery over 24-36 h (26) . Differences were presumed significant at P < 0.05.
Results
Effect ofanti-T-2 antibody on in vitro protein synthesis inhibition by T-2 toxin. To assess whether anti-T-2 could neutralize the toxic effect ofT-2 toxin in vitro, various concentrations oftoxin were incubated with various concentrations of antibody for 30 min at room temperature, then the mixtures assayed for inhibition of protein synthesis by the standard method. The data shown in Fig. 1 demonstrate a dose-responsive neutralizing effect of monoclonal anti-T-2 antibody. Although a threefold molar excess of anti-T-2 toxin was required to completely neutralize a 100% inhibitory dose of T-2 toxin in vitro (6.7 X 10-8 M antibody; 2.1 X 10-8 M T-2), significant neutralization was seen with equimolar concentrations. The failure of an isotypematched control antibody to neutralize the inhibitory effect on protein synthesis suggests that the effect was due to a true antigenantibody interaction. Furthermore, the 15H6 antibody failed to neutralize the protein synthesis inhibitory effects of two related trichothecenes, diacetoxyscirpenol and monoacetoxyscirpenol ( Fig. I B) , a finding consistent with the known binding specificity of this antibody (14) .
Effect of anti-T-2 antibody on rat survival. Injection of 1 mg/kg T-2 toxin, either alone, or with a control immunoglobulin preparation that contained no antibodies against T-2 toxin, resulted in high (90-100%) mortality as previously observed (13) . When rats were pretreated with 15H6 antibody 30 min before T-2 administration, none of the rats died throughout the experimental period (Fig. 2) . However, no differences were observed between the antibody-treated and untreated rats with regard to their blood pressure and heart rate responses to T-2 toxin; heart rate of both groups was significantly elevated as previously shown, while arterial pressure (elevated somewhat by the plasma injection) showed the same course of return to baseline levels (Fig. 3) . When two different doses of the 1 5H6 antibodies were administered 15 min after T-2 toxin, the higher dose (250 mg/ kg) provided 100% protection, while none of the control rats survived 24 h (Fig. 4) ; the lower dose (125 mg/kg) also provided substantial protection, although the survival rate was significantly lower than the full dose of the antibody (25%). Injection of the full dose of the antibody 15 min after T-2 toxin did not prevent the increase in heart rate, although significant attenuation ofthe tachycardia was seen at 2 h after T-2 toxin injection (data not shown). It is also noteworthy that in the surviving rats where hemodynamic recordings were obtained (n = 4) the mean arterial pressure was 99±7 mmHg, pulse pressure was 47±13 mmHg, and heart rate was 431±30 beats/min; these physiologic variables indicate a normal cardiovascular status at this time.
Injection of the anti-T-2 toxin antibodies (250 mg/kg) as late as 60 min after T-2 toxin administration (Fig. 5 ) also provided significant protection; 50% survival in the control and antibody-treated rats were 5 and 17 h, respectively (over threefold increased survival time). Whereas 45% of the 1 5H6-treated rats survived, none of the control rats in this study survived beyond 12 h. Injection of the 1 5H6 antibodies 60 min after T-2 toxin administration attenuated the blood pressure response at 1 h after the treatment, but other hemodynamic indices were not significantly affected by the antibody administration (data not shown). In three antibody-treated rats where adequate recordings were obtained at 24 h, all the cardiovascular variables were normal (MAP = 1 14±8, pulse pressure = 47± 10 mmHg, and heart rate = 394±25 beats/min). 
Discussion
No prophylaxis or therapy is currently available for lethal T-2 intoxication. In this study we have demonstrated for the first time that protein synthesis inhibition, the molecular mechanism of T-2 toxicity (5, 6), can be neutralized in vitro by a T-2 toxinspecific murine monoclonal antibody, and that this same antibody can be used in vivo for prophylaxis and therapy of rats exposed to a lethal dose of T-2 toxin. Using a rapidly proliferating human B lymphoblastoid cell line as indicator, the anti-T-2 monoclonal antibody T-2 neutralized the protein synthesis inhibition of T-2 toxin in vitro in a specific and dose-dependent manner. It is difficult to correlate the molecular mode of action of T-2 toxin with observed physiologic changes and morbidity seen in animals and humans. It appears that inhibition of protein synthesis is nonselective at the tissue level, although the radiomimetic effect of T-2 toxin suggests that tissues with rapidly dividing cells are most susceptible (27) . Rats exposed to lethal doses of T-2 toxin show cardiovascular changes consistent with the development of shock (9-13). Though we demonstrated a dose-dependent salutary effect of the 1 5H6 antibodies in poisoned rats, the cardiovascular changes observed in control rats were not significantly reversed in the antibody-treated rats during the first 6 h after exposure. diovascular changes in rats infused with T-2 toxin alone that closely parallel the changes seen in antibody plus toxin-treated rats (13) . In the surviving rats, the cardiovascular changes had returned to baseline levels at 24 h. A more detailed analysis of the cardiovascular parameters will be required to determine the point where improvement occurs in 1 5H6 antibody-treated rats.
The dose of anti-T-2 antibody (250 mg/kg) that conferred complete protection when administered 30 min before or 15 min after an LD1OO dose of T-2 toxin (1 mg/kg) was an amount approximately equimolar to the amount oftoxin. It is interesting to note that this ratio is similar to that required for neutralization in vitro. It is possible that the anti-T-2 antibody establishes a concentration gradient that sequesters T-2 (or HT-2) toxin in the plasma where it can be conjugated for excretion. It was also interesting to note that the 1 5H6 antibody administered 60 min after T-2 toxin was protective. By 60 min the rats were prostrate and obviously suffering from the acute effects of T-2 intoxication, yet some of the animals were rescued with the antibody. This finding is consistent with the ability to repair protein synthesis in vitro by removing the T-2 toxin (unpublished results) and similar in effect, if not mechanism, to antidigoxin antibody therapy (15, 17) and antibody-mediated reversal ofouabain toxicity (28) .
The levels of anti-T-2 that conferred protection were well above those attainable through active immunization. However, the 250 mg/kg passively administered to the rats in this study represents a physiologically acceptable dosage; 500 mg/kg of human immunoglobulin can be given to humans with no untoward effects (29) . The size difference between antibody and low molecular weight toxins like T-2 requires that large amounts of antibody be administered to achieve equimolar concentrations, even though IgG antibodies are divalent. Indeed, antibodies may even be more effective against an LDIoo dosage of a very potent toxin than against a less potent toxin since higher molar ratios of antibody to toxin can be achieved. The protein burden could be reduced somewhat by employing Fab fragments ofthe 15H6 antibody, and these fragments may also have superior pharmacokinetics as suggested by studies with other low molecular weight toxins and drugs (30) .
Mouse monoclonal antibodies have been suggested for prophylaxis and therapy in humans (31) , and early experimental evidence suggests that murine immunoglobulins, unlike most heterologous immunoglobulins, are very well tolerated in humans (32) . A higher affinity anti-T-2 antibody would probably provide better therapeutic efficacy, and human monoclonal anti-T-2 antibodies should be considered as well.
